Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab + atezolizumab + chemotherapy versus pembrolizumab + chemotherapy in previously untreated advanced non-squamous NSCLC
jRCT2031220087Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of tiragolumab, atezolizumab, pembrolizumab, pemetrexed, carboplatin and 1 more in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Started Nov 2022; status: active, not recruiting.
02
Drugs
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCT2031220087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220087.